3 healthcare shares to bring your portfolio back to life

One area of the market which I think is a great place to look for buy and hold investments is the healthcare sector.

This is because favourable tailwinds are being experienced in the sector at the moment that are expected to lead to increasing global demand for healthcare services for the next couple of decades.

In light of this, I think a number of listed healthcare companies are capable of growing earnings at a strong rate for the foreseeable future.

Three which I think are worth looking closer at are listed below. Here’s why I like them:

CSL Limited (ASX: CSL)

I think this biotherapeutics company’s recent half-year result demonstrated why it is regarded as one of the highest quality companies on the Australian share market. I believe the result has been a stand out during earnings season and shows the significant potential of its fledgling Seqirus influenza business. I feel the emergence of Seqirus should support the growth being exhibited by its core business, leading to solid profit growth over the coming years.

Nanosonics Ltd. (ASX: NAN)

Nanosonics is a leading infection control company with an increasingly popular trophon EPR product. The product is used to clean ultrasound probes and is regarded by many as being the best in its class. Pleasingly, it is also an environmentally friendly product, making it the ethical choice for ultrasound operators. Although the number of installed bases has been growing at an impressively strong rate, it still only has a 12% share of the estimated global market. This should mean it has a long runway for growth ahead of it. This could be given an additional boost if the two new products it has in development are a success.

Volpara Health Technologies Ltd (ASX: VHT)

This under-the-radar healthcare company is certainly one to watch in the future. While its shares are looking a little expensive at the moment, there is a chance it will be able to grow into this valuation. After all, demand for its technology has been growing so strongly that It is well on its way to exceeding its 200% increase in annual recurring revenue target for FY 2018. Volpara’s valuable technology allows personalised, high-quality breast cancer screening based on automated, objective measurements of breast density, compression and radiation dose.

Looking for more buy and hold options? Then don't miss out on these star stocks which have bucketloads of potential.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited. The Motley Fool Australia owns shares of VOLPARA FPO NZ. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.